GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Additional Paid-In Capital
Switch to:

Biogen (BUE:BIIB) Additional Paid-In Capital

: ARS18,017 Mil(As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's quarterly additional paid-in capital increased from Sep. 2022 (ARS0 Mil) to Dec. 2022 (ARS12,289 Mil) and increased from Dec. 2022 (ARS12,289 Mil) to Mar. 2023 (ARS18,017 Mil).

Biogen's annual additional paid-in capital increased from Dec. 2020 (ARS0 Mil) to Dec. 2021 (ARS6,888 Mil) and increased from Dec. 2021 (ARS6,888 Mil) to Dec. 2022 (ARS12,289 Mil).


Biogen Additional Paid-In Capital Historical Data

The historical data trend for Biogen's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Additional Paid-In Capital
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 6,887.52 12,288.75

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Additional Paid-In Capital Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,777.28 - - 12,288.75 18,016.56

Biogen Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Biogen Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Biogen's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines